RECRUITING

Cardiac Power Output in Cardiogenic Shock Patients

Description

The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.

Study Overview

Study Details

Study overview

The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.

Myocardial Reserve in Advanced Heart Failure Patients

Cardiac Power Output in Cardiogenic Shock Patients

Condition
Heart Failure
Intervention / Treatment

-

Contacts and Locations

Chicago

The University of Chicago, Chicago, Illinois, United States, 60637

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. LVEF ≤ 35%
  • 2. Referred for RHC for:
  • 1. Evaluation for advanced heart failure therapies, including LVAD, OHT, temporary or long-term inotrope therapy, or counter-pulsation (temporary or long-term with NuPulse device OR
  • 2. Accurate assessment of invasive hemodynamics due to worsening clinical status, OR
  • 3. Assessment of myocardial recovery for consideration of LVAD or counter-pulsation (temporary IABP or long-term with NuPulse device) decommissioning or removal OR
  • 4. Assessment of cardiac function and valvular abnormalities prior to planned valvular surgery for MR or AI
  • 3. Estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m2
  • 4. Age ≥ 18 years-old
  • 5. Intent for admission based on RHC data
  • 1. eGFR \< 30 ml/min/1.73 m2
  • 2. Severe, non-revascularized coronary artery disease
  • 3. Concurrent acute coronary syndrome
  • 4. Age \< 18 years-old
  • 5. History of significant ventricular arrhythmia without an ICD

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Chicago,

Valluvan Jeevanandam, MD, PRINCIPAL_INVESTIGATOR, University of Chicago

Study Record Dates

2025-05